Vahabi Mandana, Lofters Aisha K, Mishra Gauravi, Pimple Sharmila, Wong Josephine Pui-Hing
Daphne Cockwell School of Nursing, Toronto Metropolitan University (formerly known as Ryerson University), Toronto, ON, Canada.
Women's College Hospital, Toronto, ON, Canada.
JMIR Res Protoc. 2022 Sep 8;11(9):e35093. doi: 10.2196/35093.
Human papillomavirus (HPV) is the primary cause of cervical cancer, which is preventable through screening and early treatment. The Papanicolaou (Pap) test and visual inspection with acetic acid (VIA), which are traditionally performed in clinical settings, have been used effectively to screen for cervical cancer and precancerous changes and reduce cervical cancer mortality in high-income countries for many decades. However, these screening methods are not easily accessible to women living in low- and middle-income countries, especially women living in rural areas.
The project will use HPV self-sampling, which will be supported by a sexual health literacy intervention, to increase rural women's participation in cervical cancer screening. The objectives are to determine the effectiveness of this program in (1) increasing sexual health literacy, (2) reducing the gendered stigma of HPV and cervical cancer, and (3) promoting cervical cancer screening by using HPV self-sampling.
The pilot study will use a community-based, family-centered, mixed methods design. We will recruit 120 women aged 30 to 69 years who are underscreened or were never screened for cervical cancer, along with 120 supportive male relatives or friends from 3 low-income rural/tribal villages in Maharashtra, India. Participants will attend gender-specific sexual health education sessions, followed by a movie matinee. Data will be collected through an interviewer-administered questionnaire before and after sexual health education sessions. The questionnaire will include items on social demographics, medical histories, attitudes, sexual health stigma, cervical cancer knowledge, and screening practices. Women will self-select whether to use HPV self-sampling. Those who do not may undergo a Pap test or VIA. Participants' views regarding barriers and facilitators and their suggestions for improving access and uptake will also be elicited. This protocol was approved by the research ethics boards of Toronto Metropolitan University (formerly known as Ryerson University; reference number: REB 2020-104) and Tata Memorial Center (reference number: OIEC/3786/2021 /00003).
The Preventing Cervical Cancer in India Through Self-Sampling study was funded in January 2020 for 15 months. Due to the COVID-19 pandemic, the project was extended by 1 year. The study outcome measures will include changes in knowledge and attitudes about cervical cancer screening, the proportion of participants who self-select into each cohort, the proportion of positive test results in each cohort, and the proportion of participants with confirmed cervical cancer. Women's experiences regarding barriers and facilitators of screening uptake will be captured.
Our multifaceted work could lead to reduced cervical cancer mortality and morbidity and increased community capacity in sexual health promotion and cervical cancer prevention. The insights and lessons learned from our project can be used to inform the adaptation and scale-up of HPV self-sampling among women across India and in other countries; promote collective commitment to family-centered wellness; and support women to make healthful, personalized cervical screening decisions.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/35093.
人乳头瘤病毒(HPV)是宫颈癌的主要病因,通过筛查和早期治疗可预防宫颈癌。巴氏涂片检查(Pap)和醋酸肉眼观察法(VIA)传统上在临床环境中进行,在高收入国家已有效用于筛查宫颈癌及癌前病变,并降低宫颈癌死亡率达数十年之久。然而,生活在低收入和中等收入国家的女性,尤其是农村地区的女性,难以获得这些筛查方法。
该项目将采用HPV自我采样,并辅以性健康素养干预措施,以提高农村妇女参与宫颈癌筛查的比例。目标是确定该项目在以下方面的有效性:(1)提高性健康素养;(2)减少HPV和宫颈癌的性别耻辱感;(3)通过HPV自我采样促进宫颈癌筛查。
试点研究将采用基于社区、以家庭为中心的混合方法设计。我们将从印度马哈拉施特拉邦的3个低收入农村/部落村庄招募120名年龄在30至69岁之间、筛查不足或从未接受过宫颈癌筛查的女性,以及120名支持她们的男性亲属或朋友。参与者将参加针对性别的性健康教育课程,随后观看一场日场电影。在性健康教育课程前后,通过访谈式问卷收集数据。问卷将包括社会人口统计学、病史、态度、性健康耻辱感、宫颈癌知识和筛查实践等项目。女性将自行选择是否使用HPV自我采样。不选择自我采样的女性可接受巴氏涂片检查或VIA检查。还将了解参与者对障碍和促进因素的看法,以及她们对改善获取和接受筛查情况的建议。本方案已获得多伦多都会大学(原瑞尔森大学;参考编号:REB 2020 - 104)和塔塔纪念中心(参考编号:OIEC/3786/2021 /00003)研究伦理委员会的批准。
“通过自我采样预防印度宫颈癌”研究于2020年1月获得资助,为期15个月。由于新冠疫情,该项目延长了1年。研究结果指标将包括宫颈癌筛查知识和态度的变化、自我选择进入每个队列的参与者比例、每个队列的阳性检测结果比例以及确诊宫颈癌的参与者比例。将了解女性在筛查接受方面的障碍和促进因素的经历。
我们的多方面工作可能会降低宫颈癌的死亡率和发病率,并提高社区在性健康促进和宫颈癌预防方面的能力。我们项目的见解和经验教训可用于为印度及其他国家女性采用HPV自我采样的调整和扩大提供参考;促进对以家庭为中心的健康的集体承诺;并支持女性做出健康、个性化的宫颈癌筛查决策。
国际注册报告识别码(IRRID):PRR1 - 10.2196/35093。